Development of Gene Therapies

Strategic, Scientific, Regulatory, and Access Considerations

By: Avery McIntosh (Editor), Oleksandr Sverdlov (Editor)

Write A Review

eBook | 23 May 2024 | Edition Number 1

At a Glance

Format
ePUB

eBook

$98.99

or 4 interest-free payments of $24.75 with

Instant Digital Delivery to your Booktopia Reader App

Cell and gene therapies have become the third major drug modality in pharmaceutical medicine of the 21st century after low molecular weight and antibody drugs. The gene therapy (GTx) field is rapidly advancing, and yet there are still fundamental scientific questions that remain to be answered. Development of GTx products poses unique challenges and opportunities for drug developers. However, there is lack of a systematic exposition of the GTx product development and the pivotal role of the biostatistician in this process. Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development. Intended to provide an exposition to the GTx new product development through peer-reviewed papers written by subject matter experts in this emerging field, this book will be useful for researchers in gene therapy drug development, biostatisticians, regulators, patient advocates, graduate students, and the finance and business development community .

Key Features:

A collection of papers covering a wide spectrum of topics in gene therapies (GTx), written by leading subject matter experts.
An exposition of the core principles of GTx product development, emerging business models, industry standards, best practices, and regulatory pathways.
An exposition of statistical and innovative modeling tools for design and analysis of clinical trials of GTx.
Insights into commercial models, access hurdles, and health economics of gene therapies.
Case studies of successful GTx approvals from core team members that developed the first two FDA-approved AAV gene therapies: Luxturna and Zolgensma.
A discussion of potential benefits and hurdles to be overcome for GTx in coming years from a multi-stakeholder perspective.